Combination therapy with leflunomide and genetic engineering biological agents
The paper gives data on the use of a combination of genetic engineering biological agents (GEBAs) and leflunomide in patients with rheumatoid arthritis (RA). In accordance with the international guidelines, the majority of GEBAs should be given in a combination with methotrexate (MTX), which increas...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
IMA-PRESS LLC
2011-06-01
|
| Series: | Современная ревматология |
| Subjects: | |
| Online Access: | https://mrj.ima-press.net/mrj/article/view/353 |